Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26192970 | 0.98 | CASP2 (0.61) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL13375743 | 0.94 | CASP2 (0.55) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL24910060 | 0.93 | CASP2 (0.65) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL10798719 | 0.93 | CASP2 (0.65) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL22664244 | 0.93 | CASP2 (0.65) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL24489957 | 0.93 | CASP2 (0.65) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL10798712 | 0.93 | CASP2 (0.65) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL24132894 | 0.93 | CASP2 (0.65) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL13375742 | 0.93 | CASP2 (0.63) | CASP2NAAAFAAHDNM1EPHX2 | |
| SCHEMBL13617197 | 0.93 | FAAH (0.56) | CASP2NAAAFAAHDNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288339-B2 | GLP-1 compounds | AMGEN INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20100048468-A1 | GLP-1 COMPOUNDS | AMGEN INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048468-A1 | GLP-1 COMPOUNDS | GLP1R, IAPP, GIPR | CASP2 2613/4885NAAA 789/4885FAAH 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.